Chemoradiotherapy for Recurrent T1G3 Bladder Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03274284|
Recruitment Status : Unknown
Verified September 2017 by MokhtarDawood, Assiut University.
Recruitment status was: Not yet recruiting
First Posted : September 6, 2017
Last Update Posted : September 11, 2017
|Condition or disease||Intervention/treatment||Phase|
|Bladder Cancer||Combination Product: chemoradiation||Phase 4|
Non- muscle invasive bladder cancer (NMIBC) is a heterogeneous group of cancers. For most urologists the treatment of T1G3 tumor poses a dilemma of management.The spectrum of clinical behavior includes; T1 lesions that will not progress however T1G3 may be potentially lethal, associated with metastatic disease at the time of presentation.
The major goal of treatment for T1G3 BC should be bladder preservation whenever possible.
Intravesical therapy with Bacille Calmette Guerin (BCG) may decrease the recurrence rate by compared with transurethral resection of bladder tumor (TURBT) alone.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Chemoradiotherapy for Recurrent T1G3 Bladder Cancer After BCG Failure|
|Estimated Study Start Date :||October 2017|
|Estimated Primary Completion Date :||November 2019|
|Estimated Study Completion Date :||December 2019|
Chemoradiation in the form of cisplatin plus conformal radiotherapy 55GY/20 fractions which is biologically effective to 64GY/32 fractions fr
Combination Product: chemoradiation
chemoradiation in case of T1G3 BC after BCG failure.
- Result of chemoradiation for recurrentT1G3 BC after BCG failure [ Time Frame: followup within two years ]
treatment of 20 patients with recurrent T1G3
BC by chemoradiation to see efficacy and safety .and to reduce the number of recurrent cases and improve survival.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03274284
|Contact: moktar email@example.com|
|Contact: Diaa El Din Mohamed||+201001229936||Diaafirstname.lastname@example.org|
|Study Director:||Ahmed Moeen||Moeen3@yahoo.com|